NERV: Minerva Neurosciences, Inc.
About
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
Current Value
$2.151 Year Return
Current Value
$2.151 Year Return
Key Details
Market Cap
$14.69M
P/E Ratio
-4.8
1Y Stock Return
-58.00%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
-0.7
Strategies that include NERV
Stock's related to NERV
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| STGW | 36.75% | $832.16M | +51.63% | 0.00% |
| PRGO | 32.54% | $3.72B | -9.95% | 4.04% |
| AJX | 29.75% | $137.63M | -33.99% | 9.24% |
| FSK | 29.01% | - | - | 11.89% |
| QGEN | 26.09% | $9.05B | -1.92% | 0.00% |
| TFX | 25.84% | $8.97B | -10.85% | 0.71% |
| STAG | 25.84% | $6.62B | +1.94% | 4.09% |
| CTS | 25.73% | $1.58B | +33.53% | 0.30% |
| BLFS | 25.29% | $1.04B | +64.64% | 0.00% |
| GSM | 25.06% | $843.60M | -8.18% | 0.86% |
| GFL | 24.62% | $17.93B | +54.54% | 0.12% |
| BIPC | 24.47% | $6.13B | +36.80% | 3.74% |
| TWO | 24.24% | $1.21B | -15.84% | 15.54% |
| VRE | 24.03% | $1.70B | +35.93% | 1.29% |
| REX | 23.79% | $772.08M | +19.14% | 0.00% |
| BERY | 23.62% | $7.61B | +12.08% | 1.61% |
| TMO | 23.60% | $194.74B | +5.54% | 0.30% |
| BIP | 23.33% | $15.84B | +29.08% | 4.66% |
| RYTM | 23.10% | $3.69B | +79.50% | 0.00% |
| CLDT | 23.02% | $425.53M | -12.03% | 3.24% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GEO | -0.01% | $3.97B | +204.07% | 0.00% |
| NRC | 0.01% | $442.05M | -55.00% | 2.56% |
| SNBR | -0.03% | $263.31M | +5.09% | 0.00% |
| SNDL | -0.03% | $525.69M | +33.78% | 0.00% |
| TX | -0.04% | $6.57B | -12.10% | 9.26% |
| RYAAY | 0.05% | $24.60B | -2.90% | 0.00% |
| NVAX | 0.05% | $1.28B | +49.53% | 0.00% |
| DEI | 0.05% | $3.10B | +63.20% | 4.13% |
| ADEA | 0.05% | $1.20B | +17.45% | 1.74% |
| JBL | -0.06% | $14.39B | -2.61% | 0.25% |
| FBP | -0.07% | $3.37B | +37.39% | 3.01% |
| RNR | 0.07% | $13.74B | +23.09% | 0.58% |
| RRX | -0.08% | $11.39B | +49.31% | 0.81% |
| RWAY | -0.08% | $394.72M | -17.18% | 15.47% |
| KAR | 0.08% | $2.09B | +31.90% | 0.00% |
| LXFR | 0.08% | $387.04M | +72.02% | 3.60% |
| BXSL | -0.09% | - | - | 9.81% |
| PKE | -0.09% | $291.84M | -1.22% | 3.42% |
| EBS | 0.09% | $448.10M | +295.69% | 0.00% |
| CVM | 0.10% | $41.17M | -73.98% | 0.00% |
ETF's related to NERV
News
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.